PRESS RELEASE published on 01/04/2024 at 12:30, 2 years 1 month ago NanoViricides to Present at the Biotech Showcase in San Fransisco NanoViricides, Inc., a leader in antiviral therapies based on nanomedicines technology, is set to present at the Biotech Showcase™ 2024 in San Francisco. The presentation will include an update on the successful Phase 1 clinical trials of NV-CoV-2 Oral Syrup and Oral Gummies, which contain the novel antiviral nanomachine NV-387. The company's President will discuss how NV-387 addresses the unmet need for a broad-spectrum antiviral drug as well as its potential across multiple virus families. With its wide spectrum of antiviral activity, NV-387 has the potential to revolutionize antiviral treatment, much like antibiotics did for bacterial infections. NanoViricides Antiviral Therapies NV-387 Biotech Showcase 2024 Broad-spectrum Antiviral Drug
PRESS RELEASE published on 11/28/2023 at 12:40, 2 years 2 months ago The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides
PRESS RELEASE published on 11/15/2023 at 12:45, 2 years 2 months ago NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications
PRESS RELEASE published on 11/14/2023 at 12:45, 2 years 2 months ago Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development
PRESS RELEASE published on 10/16/2023 at 12:45, 2 years 3 months ago NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Active Against Coronaviruses as well as RSV
PRESS RELEASE published on 10/12/2023 at 12:45, 2 years 3 months ago NanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ET
PRESS RELEASE published on 08/21/2023 at 12:45, 2 years 5 months ago The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides
PRESS RELEASE published on 07/11/2023 at 12:45, 2 years 6 months ago Company’s Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in a Lethal Lung Disease Animal Model, Reports NanoViricides
PRESS RELEASE published on 07/06/2023 at 12:45, 2 years 7 months ago Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs
PRESS RELEASE published on 06/29/2023 at 12:45, 2 years 7 months ago NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun
Published on 02/07/2026 at 01:00, 1 day 14 hours ago Green Bridge Metals Can Help Secure U.S. Production of Critical Mineral Titanium
Published on 02/06/2026 at 23:10, 1 day 16 hours ago Topline Capital Management, LLC Announces Disposition of Shares of NamSys Inc.
Published on 02/06/2026 at 22:01, 1 day 17 hours ago Totec Resources Announces Listing of Shares on the Frankfurt Stock Exchange and Adoption of Omnibus Incentive Plan
Published on 02/06/2026 at 15:30, 1 day 23 hours ago Vulcan Minerals Inc. - Drilling Program Update for the Carbonear Zinc-Lead SEDEX project in Newfoundland
Published on 02/06/2026 at 13:30, 2 days 1 hour ago Redwood AI Corp. (formerly Marshall Technologies Corp.) Announces Closing of IPO and Listing of Shares on the Canadian Securities Exchange
Published on 02/07/2026 at 21:00, 18 hours 29 minutes ago Alibaba Group Debuts 'Wonder on Ice,' an Immersive AI Experience at Milan’s Sforza Castle for Milano Cortina 2026
Published on 02/07/2026 at 16:35, 22 hours 54 minutes ago The Ministry of Finance and the International Monetary Fund to launch tomorrow the second edition of the AlUla Conference for Emerging Market Economies
Published on 02/07/2026 at 16:20, 23 hours 9 minutes ago NOTICE OF SETTLEMENT APPROVAL HEARING - SHORT FORM - WAYLAND GROUP CORP., SCOTT LANGILLE, GERHARD MÜLLER, PAUL PATHAK, ERIC SILVER, MICHAEL STEIN, JOHN DOES 1-3, CANACCORD GENUITY CORP., AND RF SECURITIES CLEARING LP (FORMERLY KNOWN AS GMP SECU
Published on 02/06/2026 at 19:25, 1 day 20 hours ago Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 02/06/2026 at 17:52, 1 day 21 hours ago EQS-Adhoc: Avemio AG: Preparation of the filing for insolvency proceedings by Teltec AG, a subsidiary of Avemio AG, and potential effects on the going-concern assessment of Avemio AG
Published on 02/06/2026 at 18:22, 1 day 21 hours ago Déclaration du nombre d’actions et droits de vote au 31 janvier 2026
Published on 02/06/2026 at 18:22, 1 day 21 hours ago Disclosure of Share Capital and Voting Rights as of January 31, 2026
Published on 02/06/2026 at 16:01, 1 day 23 hours ago Notice of exercise of early redemption option of the subordinated note ISIN : FR0010093328
Published on 02/06/2026 at 16:01, 1 day 23 hours ago Exercice de l’option de remboursement de l'instrument subordonné FR0010093328
Published on 02/06/2026 at 07:54, 2 days 7 hours ago ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 janvier 2026
